ESH Video

3rd How to Diagnose and Treat Multiple Myeloma

3rd How to Diagnose and Treat Multiple Myeloma
April 15 - April 18, 2021 - E-CONFERENCE, #ESHMM2021
Chairs : Hermann Einsele, Irene Ghobrial, Sonja Zweegman


CONFERENCE UPDATE: novel coronavirus (COVID-19)

ESH 3rd How to Diagnose and Treat:

April 15-18, 2021
Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman 



In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold the conference How to Diagnose and Treat Multiple Myeloma as a virtual event.

An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of Multiple Myeloma.

The plenary E-Conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for scientific discussion and interaction.

Registered participants will further benefit from opportunities for informal scientific interaction with the world’s leading experts in the field during closed Meet the Expert sessions and E-Mentored Posters Walks.

Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME  and the PROGRAMME ON DEMAND.

– The “Live Programme” is to be found on programme page. It will be streamed live CEST time, as indicated. It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions, voting and Q&A periods, and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.

– The “Programme on Demand” available as of April 5, 2021, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

The Virtual platform will remain open from April 5 until May 18, 2021 so that participants can view and review the programme’s full scientific content at times convenient to them.

We have selected a platform with the technical capacity and environment which we feel responds to ESH objectives in terms of learning, scientific interaction and conviviality.

We hope that you will be interested in joining us for this ESH E-Conference on How to Diagnose and Treat Multiple Myeloma.

In the meantime Stay Safe!

The ESH Team



3rd How to Diagnose and Treat
Multiple Myeloma
April 15-18, 2021 
Chairs: Hermann Einsele, Irene Ghobrial, Sonja Zweegman

ESH How to Diagnose and Treat conferences are disease-specific meetings that address state-of-the-art diagnostic and clinical management.

They are based on the presentation and analysis of real clinical cases. Voting technology is used as a self-evaluation tool and to increase scientific interaction.

This meeting aims to present and debate the latest data and information in the field of Multiple Myeloma. This thought-provoking academic dialogue will address the most challenging current biology, clinical and therapeutic questions. The unique format of the program, including case-based presentations, debates and round tables provides a unique platform for discussion.

The meeting will provide clinicians and scientists with state-of-the-art recommendations regarding patient care and insight in controversies in the field.


Upon completion of this CME activity, participants should:

  • Update on the diagnosis and profiling of myeloma
  • Upfront treatment of transplant eligible and non-eligible myeloma patients
  • Treatment of relapsed myeloma patients
  • Risk-adapted therapy
  • Immune therapy
  • Diagnosis and treatment of plasma cell dyscrasias other than multiple myeloma


  • How I treat smoldering myeloma
  • How I treat newly diagnosed multiple myeloma
  • From risk stratification to risk-based therapy?
  • Should we use MRD testing to determine therapy in multiple myeloma?
  • Is there a future role of autologous stem cell transplantation?
  • How I treat relapsed multiple myeloma
  • The FDA/EMEA and Foundations perspective on multiple myeloma
  • Should every patient receive daratumumab in first line?
  • You can’t be immune for immune therapy anymore
  • Other plasma cell dyscrasias
  • The future of multiple myeloma



  • Plenary Sessions
  • Interactive Case Presentations
  • Roundtables
  • Panel Discussions
  • Debates
  • Poster Walks
  • Voting technology

Abstract submission


Clinical Cases and abstracts are eligible to be selected for an oral or a poster presentation.

Clinical Case Presentation:

  • Clinical cases must be relevant to the topic of the meeting. 
  • Maximum number of words: 500 
  • Your clinical case will be submitted to peer review. 


  • Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
  • Maximum number of words: 500 
  • Your abstract will be submitted to peer review.


Friday, April 16 from 13:30 to 14:30 CEST:
Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond
Xavier Leleu (Poitiers)
Speakers: Xavier Leleu (Poitiers), Niels van de Donk (Amsterdam), Nikhil Munshi (Boston)
This symposium is organized and sponsored by Bristol Myers Squibb

Saturday, April 17 from 09:00 to 10:00 CEST:
Management of Relapsed and Refractory Multiple Myeloma with novel monoclonal antibody-based regimens – From evidence-based considerations to clinical practice
Chair: Hartmut Goldschmidt (Heidelberg)
Philippe Moreau (Nantes), Kwee Yong (London), Sonja Zweegman (Amsterdam)
This symposium is organised and funded by Sanofi

Saturday, April 17 from 13:35 to 14:35 CEST:
New era, new data, new implications for managing multiple myeloma
Speakers: Mohamad Mohty (Paris), Philippe Moreau (Nantes)
This symposium is supported by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA

Sunday, April 18 from 10:20 to 11:20 CEST:
Anti B-cell maturation antigen (BCMA) : the fourth pillar treatment in relapsed/refractory multiple myeloma
Xavier Leleu (Poitiers)
Speakers: Javier de la Rubia (Valencia), Elena Zamagni (Bologna)
This symposium is organised and funded by GSK



The E-Conference platform is now open. Visit it now and make yourself at home!


Take a virtual tour!


Corporate partners

With the support of*:


Major E-Conference Partners


Level 1 E-Conference Partner



Level 2 E-Conference Partners


Supporting Partner


*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.



Educational Grants


The registration fee for the ESH 3rd How to Diagnose and Treat Multiple Myeloma is free.


Meet the Expert sessions:  Registration fee:  20€
These sessions are open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats are available in each session and pre-registration is therefore be required.
More information: 

Register Here